Bioisosteric replacement of dihydropyrazole of 4S-(-)-3-(4-chlorophenyl)-N-methyl-N'-[(4-chlorophenyl)-sulfonyl]-4-phenyl-4,5-dihydro-1H-pyrazole-1-caboxamidine (SLV-319) a potent CB1 receptor antagonist by imidazole and oxazole.

[1]  Bhupendra Mishra,et al.  Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology model. , 2007, Journal of medicinal chemistry.

[2]  Jonas Boström,et al.  Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists. , 2007, Bioorganic & medicinal chemistry.

[3]  G. Muccioli,et al.  Current knowledge on the antagonists and inverse agonists of cannabinoid receptors. , 2005, Current medicinal chemistry.

[4]  J. Lange,et al.  Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. , 2005, Drug discovery today.

[5]  J. Lange,et al.  Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists. , 2005, Journal of medicinal chemistry.

[6]  J. Chen,et al.  Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists. , 2005, Bioorganic & medicinal chemistry letters.

[7]  J. Pinkney,et al.  Control of obesity through the regulation of appetite , 2004 .

[8]  Donald L. Hertzog.  Recent advances in the cannabinoids , 2004 .

[9]  J. Lange,et al.  Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. , 2004, Journal of medicinal chemistry.

[10]  P. Widdowson,et al.  Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food? , 2002, Brain Research.

[11]  P. Casellas,et al.  Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. , 1998, The Journal of pharmacology and experimental therapeutics.

[12]  P. Soubrié,et al.  Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors , 1997, Psychopharmacology.

[13]  R. S. Rogers,et al.  Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). , 1997, Journal of medicinal chemistry.

[14]  J. Levin,et al.  An Alternative Procedure for the Aluminum-Mediated Conversion of Esters to Amides , 1983 .

[15]  G. Nomikos,et al.  The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats , 2005, Psychopharmacology.

[16]  L. Sorbera,et al.  Rimonabant hydrochloride: Antiobesity drug Aid to smoking cessation treatment of alcohol dependency cannabinoid CB1 antagonist , 2005 .

[17]  R. Garigipati.  An efficient conversion of nitriles to amidines , 1990 .